NCT03404193View on ClinicalTrials.gov

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myelomonocytic LeukemiaMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Myelomonocytic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid LeukemiaRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute Leukemia
Interventions
DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER